Yonhap Infomax NewsJan 2
SK Biopharmaceuticals CEO Lee Dong-hoon announced a 2024 strategy focused on global leadership, with cenobamate, radiopharmaceuticals, and AI innovation as key growth drivers, aiming to make 2026 the company’s breakthrough year in the global market.
#YonhapInfomax #SKBiopharmaceuticals #Cenobamate #GlobalLeadership #Radiopharmaceuticals #AIInnovation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98025
SK Biopharmaceuticals CEO Lee Dong-hoon Declares 2026 as 'Pivotal Year for Achieving Global Leadership'

SK Biopharmaceuticals CEO Lee Dong-hoon announced a 2024 strategy focused on global leadership, with cenobamate, radiopharmaceuticals, and AI innovation as key growth drivers, aiming to make 2026 the company’s breakthrough year in the global market.

Yonhap Infomax
Yonhap Infomax NewsMay 9, 2025
SK Biopharmaceuticals reports Q1 operating profit of 25.7 billion won, up 149% year-on-year but below market expectations, driven by U.S. sales growth of cenobamate despite temporary factors affecting revenue.
#YonhapInfomax #SKBiopharmaceuticals #Q1Earnings #OperatingProfit #Cenobamate #PharmaceuticalSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62447
SK Biopharmaceuticals Q1 Operating Profit Up 149% to 25.7 Billion Won - Below Expectations

SK Biopharmaceuticals reports Q1 operating profit of 25.7 billion won, up 149% year-on-year but below market expectations, driven by U.S. sales growth of cenobamate despite temporary factors affecting revenue.

Yonhap Infomax
Zougla.grOct 2, 2023
#Angelini #cenobamate Η Angelini Pharma λαμβάνει έγκριση στην Ελλάδα για από του στόματος αντισπασμωδικό φάρμακο https://www.zougla.gr/ygeia/pa8isis-prolipsi/i-angelini-pharma-lamvanei-egkrisi-stin-ellada-gia-apo-tou-stomatos-antispasmodiko-farmako/?utm_source=dlvr.it&utm_medium=mastodon
Η Angelini Pharma λαμβάνει έγκριση στην Ελλάδα για από του στόματος αντισπασμωδικό φάρμακο - Zougla

Δεδομένα κλινικών μελετών δείχνουν ότι πάνω από τα μισά άτομα που έλαβαν cenobamate παρουσίασαν μείωση 50% ή περισσότερο στην συχνότητα των εστιακών επιληπτικών κρίσεων.

Zougla